Yahoo · Oct 21, 2026
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
NASDAQ · AXSM
Axsome Therapeutics, Inc.
Healthcare · Biotechnology
$144.06
Down-$0.98 (-0.68%)
Updated Oct 27, 2026, 7:07 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.5B
- P/E ratio
- -32.42
- Dividend yield
- 0.00%
- 52-week range
- $123.50 – $260.19
- Volume
- 886.18K
- Avg. volume
- 522.89K
Price performance · AXSM
AXSM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
AXSM closed at $144.06 after 21 trading sessions, down 25.70% for the selected period.
- Last close
- $144.06
- Period change
- -25.70%
- Period low
- $144.06
- Period high
- $193.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $145.29 | $145.335 | $142.00 | $144.06 | 886.18K |
| Oct 23, 2026 | $154.66 | $154.74 | $143.90 | $145.04 | 1.59M |
| Oct 22, 2026 | $156.13 | $158.0783 | $154.2401 | $156.07 | 832.35K |
| Oct 21, 2026 | $158.83 | $160.8175 | $156.04 | $156.31 | 524.8K |
| Oct 20, 2026 | $157.65 | $164.79 | $157.375 | $159.58 | 653.89K |
| Oct 19, 2026 | $157.54 | $158.655 | $154.50 | $155.81 | 781.73K |
| Oct 16, 2026 | $160.43 | $160.43 | $156.09 | $157.14 | 873.15K |
| Oct 15, 2026 | $163.44 | $169.96 | $160.27 | $161.79 | 802.62K |
| Oct 14, 2026 | $156.44 | $164.00 | $155.1801 | $162.22 | 893.24K |
| Oct 13, 2026 | $166.01 | $166.55 | $155.685 | $156.32 | 1.33M |
| Oct 12, 2026 | $169.50 | $170.80 | $165.02 | $166.00 | 663K |
| Oct 9, 2026 | $170.18 | $170.6399 | $166.12 | $168.35 | 894.52K |
| Oct 8, 2026 | $170.09 | $172.275 | $166.21 | $170.08 | 1.07M |
| Oct 7, 2026 | $174.00 | $177.91 | $172.48 | $172.97 | 887.36K |
| Oct 6, 2026 | $176.52 | $176.52 | $169.30 | $174.34 | 1.37M |
| Oct 5, 2026 | $179.25 | $179.70 | $175.7301 | $177.08 | 858.89K |
| Oct 2, 2026 | $182.55 | $182.55 | $175.455 | $179.25 | 981.38K |
| Oct 1, 2026 | $184.39 | $185.6703 | $181.75 | $182.07 | 660.34K |
| Sep 30, 2026 | $186.51 | $188.00 | $184.00 | $184.39 | 1.03M |
| Sep 29, 2026 | $191.41 | $194.25 | $182.10 | $186.14 | 1.58M |
| Sep 28, 2026 | $194.98 | $198.96 | $193.1101 | $193.89 | 707.41K |
Latest AXSM news
The latest Smart Investors Daily articles mentioning AXSM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AXSM research
Overview
Company profile and research snapshot.
Company profile
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $184.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Overweight | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 29, 2026 | Deutsche Bank | Buy | — |
| Sep 25, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 23, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 21, 2026
Top 3 Health Care Stocks That Could Blast Off In October
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
Yahoo · Oct 16, 2026
2 Under-the-Radar Stocks to Buy and Hold
They aren’t the best-known corporations in the biotech industry, but they can deliver excellent long-term returns.
Yahoo · Oct 16, 2026
Does Axsome Therapeutics (AXSM) Trade Above Fair Value On Sales?
Axsome Therapeutics has delivered a very strong multi‑year share price run, yet recent pullbacks have many investors asking whether the current valuation can still be supported by its sales. With the stock now well above where it traded several years ago, the key issue is how that price lines up with the revenue the business is generating today. Over the past 5 years the stock has gained about 296.3%, which puts real pressure on the numbers to show that Axsome Therapeutics' sales can carry a...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
